| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $153,987,116 | 58 | 100 |
| Wang Xiaolin | See Remarks | 0 | $0 | 1 | $199,956 | $-199,956 |
| Wei Lin | Chief Medical Officer | 0 | $0 | 1 | $206,223 | $-206,223 |
| Patel Sushil | director | 0 | $0 | 1 | $1.05M | $-1.05M |
| Sandler Alan B. | Chief Development Officer | 0 | $0 | 2 | $1.34M | $-1.34M |
| ANDERSON ELIZABETH M | director | 0 | $0 | 1 | $1.96M | $-1.96M |
| Anders Jack | Chief Financial Officer | 0 | $0 | 8 | $7.13M | $-7.13M |
| Mancini Anthony | See Remarks | 0 | $0 | 10 | $10.22M | $-10.22M |
| Cislini Jeff | General Counsel | 0 | $0 | 9 | $14.61M | $-14.61M |
| Kim Lorence H. | director | 0 | $0 | 2 | $14.97M | $-14.97M |
| Kelsey Stephen Michael | See Remarks | 0 | $0 | 5 | $21.33M | $-21.33M |
| Horn Margaret A | Chief Operating Officer | 0 | $0 | 7 | $25.25M | $-25.25M |
| GOLDSMITH MARK A | See Remarks | 0 | $0 | 11 | $55.71M | $-55.71M |
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS …
Over the last 12 months, insiders at Revolution Medicines, Inc. have bought $0 and sold $153.99M worth of Revolution Medicines, Inc. stock.
On average, over the past 5 years, insiders at Revolution Medicines, Inc. have bought $29.26M and sold $41.44M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,304,347 shares for transaction amount of $60M was made by Schroeder Thilo (director) on 2024‑12‑05.
| 2026-10-26 | Sale | Mancini Anthony | See Remarks | 2,310 0.0011% | $186.99 | $431,947 | +3.04% | |
| 2026-09-29 | Sale | Sandler Alan B. | Chief Development Officer | 6,309 0.0029% | $202.14 | $1.28M | -6.95% | |
| 2026-09-25 | Sale | Cislini Jeff | SVP & General Counsel | 765 0.0004% | $207.32 | $158,600 | -6.66% | |
| 2026-09-25 | Sale | Mancini Anthony | See Remarks | 3,121 0.0014% | $200.54 | $625,885 | -6.66% | |
| 2026-09-24 | Sale | Mancini Anthony | See Remarks | 587 0.0003% | $200.00 | $117,400 | -3.73% | |
| 2026-09-22 | Sale | ANDERSON ELIZABETH M | director | 10,143 0.0048% | $193.04 | $1.96M | -0.23% | |
| 2026-09-18 | Sale | Mancini Anthony | See Remarks | 1,764 0.0009% | $196.94 | $347,402 | +0.97% | |
| 2026-09-16 | Sale | Kelsey Stephen Michael | See Remarks | 5,569 0.0027% | $199.24 | $1.11M | -1.59% | |
| 2026-09-16 | Sale | GOLDSMITH MARK A | See Remarks | 13,988 0.0067% | $199.24 | $2.79M | -1.59% | |
| 2026-09-16 | Sale | Horn Margaret A | Chief Operating Officer | 4,967 0.0024% | $199.24 | $989,613 | -1.59% | |
| 2026-09-16 | Sale | Anders Jack | Chief Financial Officer | 4,053 0.0019% | $199.24 | $807,513 | -1.59% | |
| 2026-09-16 | Sale | Sandler Alan B. | Chief Development Officer | 341 0.0002% | $199.24 | $67,941 | -1.59% | |
| 2026-09-16 | Sale | Cislini Jeff | SVP & General Counsel | 3,366 0.0016% | $199.24 | $670,631 | -1.59% | |
| 2026-09-16 | Sale | Mancini Anthony | See Remarks | 1,774 0.0008% | $199.24 | $353,449 | -1.59% | |
| 2026-09-11 | Sale | Kelsey Stephen Michael | See Remarks | 92,531 0.0436% | $202.36 | $18.72M | -5.03% | |
| 2026-09-10 | Sale | Mancini Anthony | See Remarks | 15,448 0.0074% | $204.16 | $3.15M | -4.73% | |
| 2026-09-08 | Sale | Kim Lorence H. | director | 17,090 0.0082% | $209.82 | $3.59M | -6.38% | |
| 2026-08-31 | Sale | Kim Lorence H. | director | 56,000 0.0263% | $203.24 | $11.38M | -4.69% | |
| 2026-08-21 | Sale | GOLDSMITH MARK A | See Remarks | 86,000 0.0407% | $209.20 | $17.99M | -4.58% | |
| 2026-08-21 | Sale | Cislini Jeff | General Counsel | 56,894 0.0269% | $209.24 | $11.9M | -4.58% |
| Kim Lorence H. | director | 0 0% | $0 | 1 | 2 | +5.12% |
| Schroeder Thilo | director | 2096612 0.9782% | $407.22M | 15 | 0 | +7.79% |
| Flynn James E | 10 percent owner | 1297589 0.6054% | $252.03M | 1 | 0 | +14.18% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$2,449,191,716 | 58 | 16.50% | $100.2B | |
$11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 247 | +76.23% | 28M | +14.87% |
| Decreased Positions | 140 | -43.21% | 22M | -11.52% |
| New Positions | 106 | New | 7M | New |
| Sold Out Positions | 38 | Sold Out | 1M | Sold Out |
| Total Postitions | 431 | +33.02% | 196M | +3.34% |
| Vanguard Group Inc | $1.24M | 8.12% | 15.66M | -98,597 | -0.63% | 2025-09-30 |
| Farallon Capital Management Llc | $1.16M | 7.58% | 14.63M | +300,000 | +2.09% | 2025-09-30 |
| Janus Henderson Group Plc | $897,355.00 | 5.88% | 11.36M | +765,327 | +7.23% | 2025-09-30 |
| Wellington Management Group Llp | $775,458.00 | 5.09% | 9.81M | -446,302 | -4.35% | 2025-09-30 |
| Baker Bros. Advisors Lp | $747,162.00 | 4.9% | 9.46M | +90,385 | +0.96% | 2025-09-30 |
| Fmr Llc | $742,921.00 | 4.87% | 9.4M | +1M | +12.93% | 2025-09-30 |
| Blackrock, Inc. | $658,059.00 | 4.32% | 8.33M | -333,635 | -3.85% | 2025-09-30 |
| Nextech Invest, Ltd. | $600,638.00 | 3.94% | 7.6M | 0 | 0% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $491,764.00 | 3.23% | 6.22M | +130,000 | +2.13% | 2025-09-30 |
| Bellevue Group Ag | $440,445.00 | 2.89% | 5.57M | +994,538 | +21.72% | 2025-09-30 |